HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies.

ABSTRACT: Gastric cancer is an aggressive disease with increasing global incidence in recent years. Human epidermal growth receptor 2 (HER2) is overexpressed in approximately 10-20% of gastric cancers. The implementation of targeted therapy against HER2 as part of the standard of care treatment in metastatic disease has improved the prognosis of this subset of patients. However, gastric cancer still has high mortality rates and urgently requires new treatment strategies. The combination of immunotherapy with HER2-targeted therapies has shown synergistic effects in preclinical models, this being the rationale behind exploring this combination in clinical trials in locally advanced and metastatic settings. Additionally, the irruption of antibody-drug conjugates and other novel HER2-targeted agents has

SUBMITTER: Pous A 

PROVIDER: S-EPMC10380453 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature